Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

US study identifies over 275 million new genetic variants from NIH research programme

Researchers could use the findings to better understand the genetic influences on health and disease

- PMLiVE

Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe

- PMLiVE

Edelman appoints Jenni Mercer as UK head of healthcare marketing

Mercer joins the communications firm from Evoke, an Inizio company

- PMLiVE

performance.io propels global reach and sets sail in Japan

The agency has also welcomed Ted Makiyi as vice president, client relations Japan and Kay Shigemori as senior content manager

- PMLiVE

THE SECRET TO EFFECTIVE IMPACT MEASUREMENT IN DIGITAL MEDICAL EDUCATION

Moving away from 'vanity' metrics towards demonstrating real value for healthcare professionals and their patients, the time is right to evolve impact measurement in digital medical education.

EPG Health

- PMLiVE

Enhancing the patient–HCP relationship in rare diseases

By Maggie Lai

Amiculum

Healthcare professionals seek independent medical education (IME)

The evolving healthcare advertising landscape

Industry experts share their insights on the emerging trends in healthcare advertising

Wiley

HCP icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why supporting HCPs matters…

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca’s Tagrisso combination approved by FDA for advanced lung cancer

An estimated 200,000 people in the US are diagnosed with lung cancer every year

- PMLiVE

FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma

Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer

- PMLiVE

Study reveals T cells could provide more protection against Omicron in future vaccines

Memory T cells were found to be more effective at fighting SARS-CoV-2 than antibodies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links